Literature DB >> 16959347

Intensified local treatment and systemic therapy significantly increase survival in patients with brain metastases from advanced breast cancer - a retrospective analysis.

Rupert Bartsch1, Sabine Fromm, Margaretha Rudas, Catharina Wenzel, Stefanie Harbauer, Karl Roessler, Klaus Kitz, Guenther G Steger, Hajo-Dirk Weitmann, Richard Poetter, Christoph C Zielinski, Karin Dieckmann.   

Abstract

BACKGROUND: Brain metastases have evolved from a rare to a frequently encountered event in advanced breast cancer due to advances in palliative systemic treatment. PATIENTS AND METHODS: All Patients treated at our centre from 1994 to 2004 with WBRT for brain metastases from breast cancer were included. We performed a multivariate analysis (Cox regression) to explore which factors are able to influence significantly cerebral time to progression (TTP) and overall survival (metastatic sites [visceral versus non-visceral], Karnofsky performance score [KPS], age, intensified local treatment [boost irradiation, neuro-surgical resection] further systemic treatment).
RESULTS: Overall 174 patients, median age 51 years, range 27-76 years, were included. Median TTP was 3 months (m), range 1-33+ m. Median overall survival was 7 m, range 1-44 m. Factors significantly influencing TTP were KPS (p = 0.002), intensified local treatment (p < 0.001), and palliative systemic treatment (p = 0.001). Factors significantly influencing survival were intensified local treatment (p = 0.004), metastatic sites (p = 0.008), KPS (p = 0.006), and palliative systemic treatment (p < 0.001).
CONCLUSION: As shown by the significant influence of metastatic sites, some patients die from their advanced systemic tumour situation before they would die from cerebral progression. In other individuals however, intensified local treatment and systemic treatment appear to influence cerebral time to progression and overall survival.

Entities:  

Mesh:

Year:  2006        PMID: 16959347     DOI: 10.1016/j.radonc.2006.08.001

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  12 in total

1.  Brain metastases from breast cancer: proposition of new prognostic score including molecular subtypes and treatment.

Authors:  Romuald Le Scodan; Christophe Massard; Ludivine Jouanneau; Florence Coussy; Maya Gutierrez; Youlia Kirova; Florence Lerebours; Alain Labib; Emmanuelle Mouret-Fourme
Journal:  J Neurooncol       Date:  2011-07-07       Impact factor: 4.130

2.  Comparison of nine prognostic scores in patients with brain metastases of breast cancer receiving radiotherapy of the brain.

Authors:  Elena Laakmann; Kerstin Riecke; Yvonne Goy; Jan F Kersten; Andreas Krüll; Volkmar Müller; Cordula Petersen; Isabell Witzel
Journal:  J Cancer Res Clin Oncol       Date:  2015-09-30       Impact factor: 4.553

3.  Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer.

Authors:  Rupert Bartsch; Andrea Rottenfusser; Catharina Wenzel; Karin Dieckmann; Ursula Pluschnig; Gabriela Altorjai; Margaretha Rudas; Robert M Mader; Richard Poetter; Christoph C Zielinski; Guenther G Steger
Journal:  J Neurooncol       Date:  2007-06-08       Impact factor: 4.130

4.  Treatment and prognosis of brain metastases from breast cancer.

Authors:  Kazuhiko Ogawa; Yoshihiko Yoshii; Tadashi Nishimaki; Nobumitsu Tamaki; Takao Miyaguni; Yukihiro Tsuchida; Yoshihiko Kamada; Takafumi Toita; Yasumasa Kakinohana; Wakana Tamaki; Shiro Iraha; Genki Adachi; Akio Hyodo; Sadayuki Murayama
Journal:  J Neurooncol       Date:  2007-09-12       Impact factor: 4.506

5.  Have changes in systemic treatment improved survival in patients with breast cancer metastatic to the brain?

Authors:  Carsten Nieder; Kirsten Marienhagen; Astrid Dalhaug; Jan Norum
Journal:  J Oncol       Date:  2008-09-23       Impact factor: 4.375

6.  Trastuzumab in the management of early and advanced stage breast cancer.

Authors:  Rupert Bartsch; Catharina Wenzel; Guenther G Steger
Journal:  Biologics       Date:  2007-03

Review 7.  Prognostic indices for brain metastases--usefulness and challenges.

Authors:  Carsten Nieder; Minesh P Mehta
Journal:  Radiat Oncol       Date:  2009-03-04       Impact factor: 3.481

8.  A case of brain metastases from breast cancer treated with whole-brain radiotherapy and eribulin mesylate.

Authors:  Carsten Nieder; Gro Aandahl; Astrid Dalhaug
Journal:  Case Rep Oncol Med       Date:  2012-08-16

9.  Presentation and course of brain metastases from breast cancer in a paranoid-schizophrenic patient: A case report.

Authors:  Astrid Dalhaug; Adam Pawinski; Jan Norum; Carsten Nieder
Journal:  Cases J       Date:  2008-09-30

10.  Prognostic scores in brain metastases from breast cancer.

Authors:  Carsten Nieder; Kirsten Marienhagen; Sabrina T Astner; Michael Molls
Journal:  BMC Cancer       Date:  2009-04-07       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.